Alkermes PLC. (ALKS) — 8-K Filings

8-K Filings (19)

• 8-K Filing — May 5, 2026
• Alkermes Enters Material Definitive Agreement — Nov 19, 2025 Risk: medium
  Alkermes plc. announced on November 18, 2025, that it has entered into a material definitive agreement. This agreement also creates a direct financial obligatio
• Alkermes plc. Files 8-K on Nov 12, 2025 — Nov 12, 2025 Risk: low
  Alkermes plc. filed an 8-K on November 12, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events
• Alkermes plc. Files 8-K: Material Agreement & Financial Update — Oct 22, 2025 Risk: medium
  On October 22, 2025, Alkermes plc. filed an 8-K report detailing a material definitive agreement and results of operations. The filing also disclosed the creati
• Alkermes plc. Files 8-K on Executive and Board Changes — Sep 12, 2025 Risk: low
  Alkermes plc. filed an 8-K on September 12, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of cer
• Alkermes plc. Files 8-K: Regulation FD & Financials — Sep 8, 2025 Risk: low
  Alkermes plc. filed an 8-K on September 8, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company'
• Alkermes plc. Files 8-K for Regulatory Disclosure — Jul 21, 2025 Risk: low
  Alkermes plc. filed an 8-K on July 21, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific fi
• Alkermes plc. Files 8-K: Director/Officer Changes & Shareholder Votes — May 21, 2025 Risk: low
  Alkermes plc. filed an 8-K on May 21, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain o
• Alkermes Sells Lybalvi Rights to Sumitomo for $200M — Apr 16, 2025 Risk: medium
  Alkermes plc. announced on April 14, 2025, that it has entered into a definitive agreement to sell its U.S. commercial rights to the schizophrenia drug Lybalvi
• Alkermes plc. Files 8-K on Financials — Jan 13, 2025 Risk: low
  Alkermes plc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosur
• Alkermes plc. Terminates Material Definitive Agreement — Dec 19, 2024 Risk: medium
  Alkermes plc. announced on December 19, 2024, the termination of a material definitive agreement. The company did not disclose the specific agreement or the cou
• Alkermes plc. Files 8-K — Dec 2, 2024 Risk: low
  Alkermes plc. filed an 8-K on December 2, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not con
• Alkermes plc. Files 8-K for Routine Disclosures — Oct 9, 2024 Risk: low
  Alkermes plc. filed an 8-K on October 9, 2024, to report on Regulation FD disclosures and file financial statements and exhibits. The filing does not contain sp
• Alkermes Files 8-K: Director Changes & Compensation Updates — May 31, 2024 Risk: low
  Alkermes plc. filed an 8-K on May 31, 2024, reporting on the departure of a director, election of new directors, and changes in officer compensation. The filing
• Alkermes plc. Files 8-K Report — Apr 9, 2024 Risk: low
  On April 9, 2024, Alkermes plc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. No
• Alkermes Appoints New Chief Medical Officer — Mar 7, 2024 Risk: medium
  Alkermes plc. announced on March 5, 2024, the appointment of Dr. Craig R. Curtis as Chief Medical Officer. Dr. Curtis previously served as Executive Vice Presid
• Alkermes Files 8-K on Financial Condition and Operations — Feb 15, 2024 Risk: low
  Alkermes Public Limited Company filed an 8-K Current Report on February 15, 2024. This filing, with CIK 0001520262, primarily concerns the company's "Results of
• Alkermes Reports Executive/Compensation Changes on Feb 1 — Feb 5, 2024
  Alkermes plc. filed an 8-K on February 5, 2024, reporting an event that occurred on February 1, 2024, related to the 'Departure of Directors or Certain Officers
• Alkermes Files Routine 8-K, Confirms Nasdaq Listing & Ireland Address — Jan 8, 2024
  Alkermes plc. filed an 8-K on January 8, 2024, to report a current event. This filing is a routine administrative update, primarily confirming the company's reg

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX